Acrivon Therapeutics (NASDAQ:ACRV) just reported results for the second quarter of 2024.
- Acrivon Therapeutics reported earnings per share of -52 cents. This was above the analyst estimate for EPS of -60 cents.
- The company did not report any revenue for the quarter.